Back
 ABCR  Vol.7 No.2 , April 2018
Role of ESR Pathway Genes in Breast Cancer: A Review
Abstract: Breast cancer is the leading cause of death in women. Prognosis of breast cancer is often pessimistic because the tumors are prone to metastasizing to the bone, brain, and lung. The estrogen signaling receptor (ESR) pathway contains 39 main genes and proteins which makes it one of the larger signaling pathways. Predominately this pathway and the proteins within are involved in breast growth and development, making it a prospective area of study for breast cancer. While the healthy ESR pathway has been constructed and is well established, a mechanistic model of mutated genes of ESR pathway has not been delved upon. Such mutated models could be utilized for selecting combinational targets for drug therapies, as well as elucidating crosstalk between other pathways and feedback mechanisms. To construct the mutated models of the ESR pathway it is imperative to assess what is currently understood in the literature and what inconsistencies exist in order to resolve them. Without this information, a model of the ESR pathway will be unreliable and likely unproductive. This review is the detailed literature survey of the biological studies performed on ESR pathways genes, and their respective roles in breast cancer. Furthermore, the details mentioned in the review can be beneficial for the integrated study of the ESR pathway genes, which includes, structural and dynamics study of the genes products, to have a holistic understanding of the cancer mechanism.
Cite this paper: Kumar, D. , Myers, M. , Al Homsi, U. and Ilyin, V. (2018) Role of ESR Pathway Genes in Breast Cancer: A Review. Advances in Breast Cancer Research, 7, 134-186. doi: 10.4236/abcr.2018.72010.
References

[1]   Siegel, R.L., Miller, K.D. and Jemal, A. (2016) Cancer Statistics. CA: A Cancer Journal for Clinicians, 66, 7-30.
https://doi.org/10.3322/caac.21332

[2]   Youlden, D.R., Cramb, S.M., Yip, C.H. and Baade, P.D. (2014) Incidence and Mortality of Female Breast Cancer in the Asia-Pacific Region. Cancer Biology & Medicine, 11, 101-115.

[3]   Saha Roy, S. and Vadlamudi, R.K. (2012) Role of Estrogen Receptor Signaling in Breast Cancer Metastasis. International Journal of Breast Cancer, 2012, Article ID: 654698.
https://doi.org/10.1155/2012/654698

[4]   Pechkova, E., Bragazzi, N., Bozdaganyan, M., Belmonte, L. and Nicolini, C. (2014) A Review of the Strategies for Obtaining High-Quality Crystals Utilizing Nanotechnologies and Microgravity. Critical Reviews in Eukaryotic Gene Expression, 24, 325-339.
https://doi.org/10.1615/CritRevEukaryotGeneExpr.2014008275

[5]   Chitrala, K.N. and Yeguvapalli, S. (2014) Computational Screening and Molecular Dynamic Simulation of Breast Cancer Associated Deleterious Non-Synonymous Single Nucleotide Polymorphisms in TP53 Gene. PLoS ONE, 9, e104242.
https://doi.org/10.1371/journal.pone.0104242

[6]   Ozbligin, K., Karaca, F., Turan, A., Kose, C., Vatansever, S. and Ozcakir, T. (2015) The Higher Heparin-Binding Epidermal Growth Factor (HB-EGF) in Missed Abortion. Taiwanese Journal of Obstetrics and Gynecology, 54, 13-18.
https://doi.org/10.1016/j.tjog.2013.08.011

[7]   Vinante, F. and Rigo, A. (2013) Heparin-Binding Epidermal Growth Factor-Like Growth Factor/Diphtheria Toxin Receptor in Normal and Neoplastic Hematopoiesis. Toxins, 5, 1180-1201.
https://doi.org/10.3390/toxins5061180

[8]   Sato, S., Drake, A.W., Tsuji, I. and Fan, J. (2012) Apotent Anti-HB-EGF Monoclonal Antibody Inhibits Cancer Cell Proliferation and Multiple Angio-Genic Activities of HB-EGF. PLoS ONE, 7, e51964.
https://doi.org/10.1371/journal.pone.0051964

[9]   Zhou, Z.N., Sharma, V.P., Beaty, B.T., et al. (2014) Autocrine HBEGF Expression Promotes Breast Cancer Intravasation, Metastasis and Macrophage-Independent Invasion in Vivo. Oncogene, 33, 3784-3793.
https://doi.org/10.1038/onc.2013.363

[10]   Eccles, S.A. (2011) The Epidermal Growth factor Receptor/Erb-B/HER Family in Normal and Malignant Breast Biology. The International Journal of Developmental Biology, 55, 685-696.
https://doi.org/10.1387/ijdb.113396se

[11]   Burness, M.L., Grushko, T.A. and Olopade, O.I. (2010) Epidermal Growth Factor Receptor in Triplenegative and Basal-Like Breast Cancer: Promising Clinical Target or Only a Marker? The Cancer Journal, 16, 23-32.
https://doi.org/10.1097/PPO.0b013e3181d24fc1

[12]   Secq, V., Villeret, J., Fina, F., Carmassi, M., Carcopino, X., Garcia, S., et al. (2014) Triple Negative Breast Carcinoma EGFR Amplification Is Not Associated with EGFR, Kras or ALK Mutations. British Journal of Cancer, 110, 1045-1052.
https://doi.org/10.1038/bjc.2013.794

[13]   Jin, Q. and Esteva, F.J. (2008) Cross-Talk between the ErbB/HER Family and the Type I Insulin-Like Growth Factor Receptor Signaling Pathway in Breast Cancer. Journal of Mammary Gland Biology and Neoplasia, 13, 485-498.
https://doi.org/10.1007/s10911-008-9107-3

[14]   Zhang, C. and Sarkar, D.K. (2012) β-Endorphin Neuron Transplantation: A Possible Novel Therapy for Cancer Prevention. Oncoimmunology, 1, 552-554.
https://doi.org/10.4161/onci.19335

[15]   Sloan, E.K., Priceman, S.J., Cox, B.F., et al. (2010) Sympathetic Nervous System Induces a Metastatic Switch in Primary Breast Cancer. Cancer Research, 70, 7042-7052.
https://doi.org/10.1158/0008-5472.CAN-10-0522

[16]   Sarkar, D.K., Zhang, C., Murugan, S., Dokur, M., Boyadjieva, N.I., Ortiguela, M., et al. (2011) Transplantation of β-Endorphin Neurons into the Hypothalamus Promotes Immune Function and Restricts the Growth and Metastasis of Mammary Carcinoma. Cancer Research, 71, 6282-6291.
https://doi.org/10.1158/0008-5472.CAN-11-1610

[17]   Benke, D. (2010) Mechanisms of GABAB Receptor Exocytosis, Endocytosis, and Degradation. Advances in Pharmacology, 58, 93-111.
https://doi.org/10.1016/S1054-3589(10)58004-9

[18]   Pinard, A., Seddik, R. and Bettler, B. (2010) GABAB Receptors: Physiological Functions and Mechanisms of Diversity. Advances in Pharmacology, 58, 231-255.
https://doi.org/10.1016/S1054-3589(10)58010-4

[19]   Luscher, C. and Slesinger, P.A. (2010) Emerging Roles for G Protein-Gated Inwardly Rectifying Potassium (GIRK) Channels in Health and Disease. Nature Reviews Neuroscience, 11, 301-315.
https://doi.org/10.1038/nrn2834

[20]   Jiang, X., Su, L., Zhang, Q., He, C., Zhang, Z., Yi, P. and Liu, J. (2012) GABAB Receptor Complex as a Potential Target for Tumor Therapy. Journal of Histochemistry & Cytochemistry, 60, 269-279.
https://doi.org/10.1369/0022155412438105

[21]   Shu, Q., Liu, J., Liu, X., Zhao, S., Li, H., Tan, Y. and Xu, J. (2016) GABABR/GSK-3β/NF-κB Signaling Pathway Regulates the Proliferation of Colorectal Cancer Cells. Cancer Medicine, 5, 1259-1267.
https://doi.org/10.1002/cam4.686

[22]   Cooper, A., Grigoryan, G., Guy-David, L., Tsoory, M.M., Chen, A. and Reuveny, E. (2012) Trisomy of the G Protein-Coupled K+ Channel Gene, Kcnj6, Affects Reward Mechanisms, Cognitive Functions, and Synaptic Plasticity in Mice. Proceedings of the National Academy of Sciences of the United States of America, 109, 2642-2647.
https://doi.org/10.1073/pnas.1109099109

[23]   Jiang, X., Su, L., Zhang, Q., et al. (2012) GABAB Receptor Complex as a Potential Target for Tumor Therapy. Journal of Histochemistry & Cytochemistry, 60, 269-279.
https://doi.org/10.1369/0022155412438105

[24]   Geng, Y., Bush, M. and Fan, Q.R. (2013) Structural Mechanism of Ligand Activation in Human GABA(B) Receptor. Nature, 504, 254-259.
https://doi.org/10.1038/nature12725

[25]   Rezania, S., Li, C., Kammerer, S., Gorischek, A., Devaney, T., Zarnani, A.H., Baeuernhofer, T. and Schreibmayer, W. (2014) G-Protein Activated Inwardly Rectifying Potassium Channels Control Motility of Breast Cancer Cells. Biophysical Journal, 106, 543.
https://doi.org/10.1016/j.bpj.2013.11.3026

[26]   Seebahn, A., Sticht, H. and Enz, R. (2013) Expression, Purification, and Structural Analysis of Intracellular C-Termini from Metabotropic Glutamate Receptors. Methods in Enzymology, 520, 257-279.
https://doi.org/10.1016/B978-0-12-391861-1.00012-5

[27]   Willard, S.S. and Koochekpour, S. (2013) Glutamate Signaling in Benign and Malignant Disorders: Current Status, Future Perspectives, and Therapeutic Implications. International Journal of Biological Sciences, 9, 728-742.
https://doi.org/10.7150/ijbs.6475

[28]   Esseltine, J.L., Ribeiro, F.M. and Ferguson, S.S. (2012) Rab8 Modulates Metabotropic Glutamate Receptor Subtype 1 Intracellular Trafficking and Signaling in a Protein Kinase C-Dependent Manner. Journal of Neuroscience, 32, 16933-16942.
https://doi.org/10.1523/JNEUROSCI.0625-12.2012

[29]   Esseltine, J.L., Willard, M.D., Wulur, I.H., et al. (2013) Somatic Mutations in GRM1 in Cancer Alter Metabotropic Glutamate Receptor 1 Intracellular Localization and Signaling. Molecular Pharmacology, 83, 770-780.
https://doi.org/10.1124/mol.112.081695

[30]   Speyer, C.L., Smith, J.S., Banda, M., DeVries, J.A., Mekani, T. and Gorski, D.H. (2012) Metabotropic Glutamate Receptor-1: A Potential Therapeutic Target for the Treatment of Breast Cancer. Breast Cancer Research and Treatment, 132, 565-573.
https://doi.org/10.1007/s10549-011-1624-x

[31]   Banda, M., Speyer, C.L., Semma, S.N., et al. (2014) Metabotropic Glutamate Receptor-1 Contributes to Progression in Triple Negative Breast Cancer. PLoS ONE, 9, e81126.
https://doi.org/10.1371/journal.pone.0081126

[32]   Speyer, C.L., Hachem, A.H., Assi, A.A., Johnson, J.S., DeVries, J.A. and Gorski, D.H. (2014) Metabotropic Glutamate Receptor-1 as a Novel Target for the Antiangiogenic Treatment of Breast Cancer. PLoS ONE, 9, e88830.
https://doi.org/10.1371/journal.pone.0088830

[33]   Sen, B. and Johnson, F.M. (2011) Regulation of SRC Family Kinases in Human Cancers. Journal of Signal Transduction, 2011, Article ID: 865819.
https://doi.org/10.1155/2011/865819

[34]   Banerjee, M., Duan, Q. and Xie, Z. (2015) SH2 Ligand-Like Effects of Second Cytosolic Domain of Na/K-ATPase α1 Subunit on Src Kinase. PLoS ONE, 10, e0142119.
https://doi.org/10.1371/journal.pone.0142119

[35]   Fan, P., McDaniel, R.E., Kim, H.R., Clagett, D., Haddad, B. and Jordan, V.C. (2012) Modulating Therapeutic Effects of the c-Src Inhibitor via Estrogen Receptor and HER2 in Breast Cancer Cell Lines. European Journal of Cancer, 48, 3488-3498.
https://doi.org/10.1016/j.ejca.2012.04.020

[36]   Thakur, R., Trivedi, R., Rastogi, N., Singh, M. and Mishra, D.P. (2015) Inhibition of STAT3, FAK and Src Mediated Signaling Reduces Cancer Stem Cell Load, Tumorigenic Potential and Metastasis in Breast Cancer. Scientific Reports, 5, Article No. 10194.
https://doi.org/10.1038/srep10194

[37]   Zhang, S., Huang, W.C., Li, P., et al. (2011) Combating Trastuzumab Resistance by Targeting SRC, a Common Node Downstream of Multiple Resistance Pathways. Nature Medicine, 17, 461-469.
https://doi.org/10.1038/nm.2309

[38]   Rexer, B.N., Ham, A.J., Rinehart, C., et al. (2011) Phosphoproteomic Mass Spectrometry Profiling Links Src Family Kinases to Escape from HER2 Tyrosine Kinase Inhibition. Oncogene, 30, 4163-4174.
https://doi.org/10.1038/onc.2011.130

[39]   Elsberger, B. (2014) Translational Evidence on the Role of Src Kinase and Activated Src Kinase in Invasive Breast Cancer. Critical Reviews in Oncology/Hematology, 89, 343-351.
https://doi.org/10.1016/j.critrevonc.2013.12.009

[40]   Formisano, L., Nappi, L., Rosa, R., et al. (2014) Epidermal Growth Factor-Receptor Activation Modulates Src-Dependent Resistance to Lapatinib in Breast Cancer Models. Breast Cancer Research: BCR, 16, R45.
https://doi.org/10.1186/bcr3650

[41]   Liu, Z., Zhang, J., Wu, L., Liu, J. and Zhang, M. (2014) Overexpression of GNAO1 Correlates with Poor Prognosis in Patients with Gastric Cancer and Plays a Role in Gastric Cancer Cell Proliferation and Apoptosis. International Journal of Molecular Medicine, 33, 589-596.
https://doi.org/10.3892/ijmm.2013.1598

[42]   El-Haibi, C.P., Sharma, P., Singh, R., et al. (2013) Differential G Protein Sub-Unit Expression by Prostate Cancer Cells and Their Interaction with CXCR5. Molecular Cancer, 12, 64.
https://doi.org/10.1186/1476-4598-12-64

[43]   Urtatiz, O. and Van Raamsdonk, C.D. (2016) Gnaq and Gna11 in the Endothelin Signaling Pathway and Melanoma. Frontiers in Genetics, 7, 59.
https://doi.org/10.3389/fgene.2016.00059

[44]   Kan, Z., Jaiswal, B.S., Stinson, J., et al. (2010) Diverse Somatic Mutation Patterns and Pathway Alterations in Human Cancers. Nature, 466, 869-873.
https://doi.org/10.1038/nature09208

[45]   Bollig-Fischer, A., Michelhaugh, S.K., Wijesinghe, P., et al. (2015) Cytogenomic Profiling of Breast Cancer Brain Metastases Reveals Potential for Repurposing Targeted Therapeutics. Oncotarget, 6, 14614-14624.
https://doi.org/10.18632/oncotarget.3786

[46]   Garcia-Murillas, I., Sharpe, R., Pearson, A., et al. (2014) An siRNA Screen Identifies the GNAS Locus as a Driver in 20q Amplified Breast Cancer. Oncogene, 33, 2478-2486.
https://doi.org/10.1038/onc.2013.202

[47]   Yagi, H., et al. (2011) A Synthetic Biology Approach Reveals a CXCR4-G13-Rho Signaling Axis Driving Transendothelial Migration of Metastatic Breast Cancer Cells. Science Signaling, 4, ra60.
https://doi.org/10.1126/scisignal.2002221

[48]   Ahmed, Z., Timsah, Z., Suen, K.M., et al. (2015) Grb2 Monomer-Dimer Equilibrium Determins Normal versus Oncogenic Function. Nature Communications, 6, 8007.
https://doi.org/10.1038/ncomms9007

[49]   Lin, C.C., Melo, F.A., Ghosh, R., et al. (2012) Inhibition of Basal FGF Receptor Signaling by Dimeric Grb2. Cell, 149, 1514-1524.
https://doi.org/10.1016/j.cell.2012.04.033

[50]   Yin, J., Cai, Z., Zhang, L., et al. (2013) A Recombined Fusion Protein PTD-Grb2-SH2 Inhibits the Proliferation of Breast Cancer Cells in Vitro. International Journal of Oncology, 42, 1061-1069.
https://doi.org/10.3892/ijo.2013.1768

[51]   Ahmed, Z., Lin, C.-C., Suen, K.M., et al. (2013) Grb2 Controls Phosphorylation of FGFR2 by Inhibiting Receptor Kinase and Shp2 Phosphatase Activity. The Journal of Cell Biology, 200, 493-504.
https://doi.org/10.1083/jcb.201204106

[52]   Bisson, N., James, D.A., Ivosev, G., et al. (2011) Selected Reaction Monitoring Mass Spectrometry Reveals the Dynamics of Signaling through the GRB2 Adaptor. Nature Biotechnology, 29, 653-658.
https://doi.org/10.1038/nbt.1905

[53]   Luey, B.C. and May, F.E.B. (2016) Insulin-Like Growth Factors Are Essential to Prevent Anoikis in Oestrogen-Responsive Breast Cancer Cells: Importance of the Type I IGF Receptor and PI3-Kinase/Akt Pathway. Molecular Cancer, 15, 8.
https://doi.org/10.1186/s12943-015-0482-2

[54]   Zhang, Y., Xu, G., Liu, G., et al. (2016) miR-411-5p Inhibits Proliferation and Metastasis of Breast Cancer Cell via Targeting GRB2. Biochemical and Biophysical Research Communications.

[55]   Davies, M.A. (2011) Regulation, Role, and Targeting of Akt in Cancer. Journal of Clinical Oncology, 29, 4715-4717.
https://doi.org/10.1200/JCO.2011.37.4751

[56]   Diez, H., Garrido, J.J. and Wandosell, F. (2012) Specific Roles of Akt Iso Forms in Apoptosis and Axon Growth Regulation in Neurons. PLoS ONE, 7, e32715.
https://doi.org/10.1371/journal.pone.0032715

[57]   Liu, W., Bagaitkar, J. and Watabe, K. (2007) Roles of Akt Signal in Breast Cancer. Frontiers in Bioscience, 12, 4011-4019.
https://doi.org/10.2741/2367

[58]   Fabi, F. and Asselin, E. (2014) Expression, Activation, and Role of AKT Isoforms in the Uterus. Reproduction, 148, R85-R95.
https://doi.org/10.1530/REP-14-0270

[59]   Fox, E.M., Kuba, M.G., Miller, T.W., Davies, B.R. and Arteaga, C.L. (2013) Autocrine IGF-I/Insulin Receptor Axis Compensates for Inhibition of AKT in ER-Positive Breast Cancer Cells with Resistance to Estrogen Deprivation. Breast Cancer Research: BCR, 15, R55.
https://doi.org/10.1186/bcr3449

[60]   Paplomata, E., Zelnak, A. and O’Regan, R. (2013) Everolimus: Side Effect Profile and Management of Toxicities in Breast Cancer. Breast Cancer Research and Treatment, 140, 453-462.
https://doi.org/10.1007/s10549-013-2630-y

[61]   Wong, C., Wang, X., Smith, D., Reddy, K. and Chen, S. (2012) AKT-Aro and HER2-Aro, Models for De Novo Resistance to Aromatase Inhibitors, Molecular Characterization and Inhibitor Response Studies. Breast Cancer Research and Treatment, 134, 671-681.
https://doi.org/10.1007/s10549-012-2105-6

[62]   O’Hurley, G., Daly, E., O’Grady, A., et al. (2014) Investigation of Molecular Alterations of AKT-3 in Triple-Negative Breast Cancer. Histopathology, 64, 660-670.
https://doi.org/10.1111/his.12313

[63]   Fernandez-Medarde, A. and Santos, E. (2011) Ras in Cancer and Developmental Diseases. Genes & Cancer, 2, 344-358.
https://doi.org/10.1177/1947601911411084

[64]   Myers, M.B., Banda, M., McKim, K.L., Wang, Y., Powell, M.J. and Parsons, B.L. (2016) Breast Cancer Heterogeneity Examined by High-Sensitivity Quantification of PIK3CA, KRAS, HRAS, and BRAF Mutations in Normal Breast and Ductal Carcinomas. Neoplasia, 18, 253-263.
https://doi.org/10.1016/j.neo.2016.03.002

[65]   Giltnane, J.M. and Balko, J.M. (2014) Rationale for Targeting the Ras/MAPK Pathway in Triple-Negative Breast Cancer. Discovery Medicine, 17, 275-283.

[66]   Niemitz, E. (2013) Ras Pathway Activation in Breast Cancer. Nature Genetics, 45, 1273.
https://doi.org/10.1038/ng.2817

[67]   Sanchez-Munoz, A., Gallego, E., de Luque, V., et al. (2010) Lack of Evidence for KRAS Oncogenic Mutations in Triple-Negative Breast Cancer. BMC Cancer, 10, 136.
https://doi.org/10.1186/1471-2407-10-136

[68]   Grob, T.J., Heilenkotter, U., Geist, S., et al. (2012) Rare Oncogenic Mutations of Predictive Markers for Targeted Therapy in Triple-Negative Breast Cancer. Breast Cancer Research and Treatment, 134, 561-567.
https://doi.org/10.1007/s10549-012-2092-7

[69]   Pereira, C.B., Leal, M.F., De Souza, C.R., et al. (2013) Prognostic and Predictive Significance of MYC and KRAS Alterations in Breast Cancer from Women Treated with Neoadjuvant Chemotherapy. PLoS ONE, 8, e60576.
https://doi.org/10.1371/journal.pone.0060576

[70]   Paranjape, T., Heneghan, H., Lindner, R., et al. (2011) A 3t-Untranslated Region KRAS Variant and Triple-Negative Breast Cancer: A Case-Control and Genetic Analysis. The Lancet Oncology, 12, 377-386.
https://doi.org/10.1016/S1470-2045(11)70044-4

[71]   Jancik, S., Drabek, J., Radzioch, D. and Hajduch, M. (2010) Clinical Relevance of KRAS in Human Cancers. Journal of Biomedicine and Biotechnology, 2010, Article ID: 150960.
https://doi.org/10.1155/2010/150960

[72]   Zheng, Z.Y., Tian, L., Bu, W., et al. (2015) Wild Type N-Ras, Overexpressed in Basal-Like Breast Cancer, Promotes Tumor Formation by Inducing IL8 Secretion via JAK2 Activation. Cell Reports, 12, 511-524.
https://doi.org/10.1016/j.celrep.2015.06.044

[73]   Yong, H.Y., Hwang, J.S., Son, H., et al. (2011) Identification of H-Ras-Specific Motif for the Activation of Invasive Signaling Program in Human Breast Epithelial Cells. Neoplasia, 13, 98-107.
https://doi.org/10.1593/neo.101088

[74]   De, S., Dermawan, J.K.T. and Stark, G.R. (2014) EGF Receptor Uses SOS1 to Drive Constitutive Activation of NFκB in Cancer Cells. Proceedings of the National Academy of Sciences of the United States of America, 111, 11721-11726.
https://doi.org/10.1073/pnas.1412390111

[75]   Denayer, E., Devriendt, K., De Ravel, T., et al. (2010) Tumor Spectrum in Children with Noonan Syndrome and SOS1 or RAF1 Mutations. Genes Chromosomes Cancer, 49, 242-252.

[76]   Rojas, J.M., Oliva, J.L. and Santos, E. (2011) Mammalian Son of Sevenless Guanine Nucleotide Exchange Factors: Old Concepts and New Perspectives. Genes & Cancer, 2, 298-305.
https://doi.org/10.1177/1947601911408078

[77]   Pierre, S., Bats, A.S. and Coumoul, X. (2011) Understanding SOS (Son of Sevenless). Biochemical Pharmacology, 82, 1049-1056.
https://doi.org/10.1016/j.bcp.2011.07.072

[78]   Field, L.A., Love, B., Devarmin, B., Hooke, J.A., Shriver, C.D. and Ellsworth, R.E. (2012) Identification of Differentially Expressed Genes in Breast Tumors from African American Compared with Caucasian Women. Cancer, 118, 1334-1344.
https://doi.org/10.1002/cncr.26405

[79]   Boyle, P. (2012) Triple-Negative Breast Cancer: Epidemiological Considerations and Recommendations. Annals of Oncology, 23, vi7-vi12.
https://doi.org/10.1093/annonc/mds187

[80]   Rosse, C., Linch, M., Kermorgant, S., Cameron, A.J., Boeckeler, K. and Parker, P.J. (2010) PKC and the Control of Localized Signal Dynamics. Nature Reviews Molecular Cell Biology, 11, 103-112.
https://doi.org/10.1038/nrm2847

[81]   Urtreger, A.J., Kazanietz, M.G. and Bal de Kier Joffe, E.D. (2012) Contribution of Individual PKC Isoforms to Breast Cancer Progression. IUBMB Life, 64, 18-26.
https://doi.org/10.1002/iub.574

[82]   Evans, L.M., Cowey, S.L., Siegal, G.P. and Hardy, R.W. (2009) Stearate Preferentially Induces Apoptosis in Human Breast Cancer Cells. Nutrition and Cancer, 61, 746-753.
https://doi.org/10.1080/01635580902825597

[83]   Debald, M., Franken, S., Heukamp, L.C., et al. (2011) Identification of Specific Nuclear Structural Protein Alterations in Human Breast Cancer. Journal of Cellular Biochemistry, 112, 3176-3184.
https://doi.org/10.1002/jcb.23249

[84]   Yokokura, S., Yurimoto, S., Matsuoka, A., et al. (2014) Calmodulin Antagonists Induce Cell Cycle Arrest and Apoptosis in Vitro and Inhibit Tumor Growth in Vivo in Human Multiple Myeloma. BMC Cancer, 14, 882.
https://doi.org/10.1186/1471-2407-14-882

[85]   Berchtold, M.W. and Villalobo, A. (2014) The Many Faces of Calmodulin in Cell Proliferation, Programmed Cell Death, Autophagy, and Cancer. Biochimica et Biophysica Acta, 1843, 398-435.
https://doi.org/10.1016/j.bbamcr.2013.10.021

[86]   Fancy, R.M., Wang, L., Zeng, Q., et al. (2016) Characterization of the Interactions between Calmodulin and Death Receptor 5 in Triple-Negative and Estrogen Receptor-Positive Breast Cancer Cells: An Integrated Experimental and Computational Study. The Journal of Biological Chemistry, 291, 12862-12870.
https://doi.org/10.1074/jbc.M116.727727

[87]   Debald, M., Schildberg, F.A., Linke, A., et al. (2013) Specific Expression of K63-Linked Ubiquitination of Calmodulin-Like Protein 5 in Breast Cancer of Premenopausal Patients. Journal of Cancer Research and Clinical Oncology, 139, 2125-2132.
https://doi.org/10.1007/s00432-013-1541-y

[88]   White, C.D., Li, Z. and Sacks, D.B. (2011) Calmodulin Binds HER2 and Modulates HER2 Signaling. Biochimica et Biophysica Acta, 1813, 1074-1082.
https://doi.org/10.1016/j.bbamcr.2010.12.016

[89]   Samatar, A.A. and Poulikakos, P.I. (2014) Targeting RAS-ERK Signaling in Cancer: Promises and Challenges. Nature Reviews Drug Discovery, 13, 928-942.
https://doi.org/10.1038/nrd4281

[90]   Matallanas, D., Birtwistle, M., Romano, D., et al. (2011) Raf Family Kinases: Old Dogs Have Learned New Tricks. Genes & Cancer, 2, 232-260.
https://doi.org/10.1177/1947601911407323

[91]   An, S., Yang, Y., Ward, R., Liu, Y., Guo, X.X. and Xu, T.R. (2015) Raf-Interactome in Tuning the Complexity and Diversity of Raf Function. The FEBS Journal, 282, 32-53.
https://doi.org/10.1111/febs.13113

[92]   Santarpia, L., Qi, Y., Stemke-Hale, K., et al. (2012) Mutation Profiling Identifies Numerous Rare Drug Targets and Distinct Mutation Patterns in Different Clinical Subtypes of Breast Cancers. Breast Cancer Research and Treatment, 134, 333-343.
https://doi.org/10.1007/s10549-012-2035-3

[93]   Yang, G., Wu, D., Zhu, J., et al. (2013) Upregulation of miR-195 Increases the Sensitivity of Breast Cancer Cells to Adriamycin Treatment through Inhibition of Raf-1. Oncology Reports, 30, 877-889.
https://doi.org/10.3892/or.2013.2532

[94]   Glenisson, M., Vacher, S., Callens, C., et al. (2012) Identification of New Candidate Therapeutic Target Genes in Triple-Negative Breast Cancer. Genes & Cancer, 3, 63-70.
https://doi.org/10.1177/1947601912449832

[95]   Chang, C.-J., Yang, J.-Y., Xia, W., et al. (2011) EZH2 Promotes Expansion of Breast Tumor Initiating Cells through Activation of RAF1-β-Catenin Signaling. Cancer Cell, 19, 86-100.
https://doi.org/10.1016/j.ccr.2010.10.035

[96]   Saini, K.S., Loi, S., De Azambuja, E., et al. (2013) Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK Pathways in the Treatment of Breast Cancer. Cancer Treatment Reviews, 39, 935-946.
https://doi.org/10.1016/j.ctrv.2013.03.009

[97]   Ozel, C., Seidel, J., Meyer-Staeckling, S., et al. (2012) Hybrid Cells Derived from Breast Epithelial Cell/Breast Cancer Cell Fusion Events Show a Differential RAF-AKT Crosstalk. Cell Communication and Signaling: CCS, 10, 10.
https://doi.org/10.1186/1478-811X-10-10

[98]   Yi, T., Zhai, B., Yu, Y., et al. (2014) Quantitative Phosphoproteomic Analysis Reveals System-Wide Signaling Pathways Downstream of SDF-1/CXCR4 in Breast Cancer Stem Cells. Proceedings of the National Academy of Sciences of the United States of America, 111, E2182-E2190.
https://doi.org/10.1073/pnas.1404943111

[99]   Akinleye, A., Furqan, M., Mukhi, N., Ravella, P. and Liu, D. (2013) MEK and the Inhibitors: From Bench to Bedside. Journal of Hematology & Oncology, 6, 27.
https://doi.org/10.1186/1756-8722-6-27

[100]   Roskoski, R. (2012) ERK1/2 MAP Kinases: Structure, Function and Regulation. Pharmacological Research, 66, 105-143.
https://doi.org/10.1016/j.phrs.2012.04.005

[101]   Zhao, Y. and Adjei, A.A. (2014) The Clinical Development of MEK Inhibitors. Nature Reviews Clinical Oncology, 11, 385-400.
https://doi.org/10.1038/nrclinonc.2014.83

[102]   Maiello, M.R., D’Alessio, A., Bevilacqua, S., Gallo, M., Normanno, N. and De Luca, A. (2015) EGFR and MEK Blockade in Triple Negative Breast Cancer Cells. Journal of Cellular Biochemistry, 116, 2668-2685.
https://doi.org/10.1002/jcb.25220

[103]   Kim, S., Lee, J., Jeon, M., Lee, J.E. and Nam, S.J. (2016) MEK-Dependent IL-8 Induction Regulated the Invasiveness of Triple-Negative Breast Cancer Cells. Tumor Biology, 37, 4991-4999.
https://doi.org/10.1007/s13277-015-4345-7

[104]   Storer, C.L., Dickey, C.A., Galigniana, M.D., Rein, T. and Cox, M.B. (2011) FKBP51 and FKBP52 in Signaling and Disease. Trends in Endocrinology and Metabolism: TEM, 22, 481-490.
https://doi.org/10.1016/j.tem.2011.08.001

[105]   Sivils, J.C., Storer, C.L., Galigniana, M.D. and Cox, M.B. (2011) Regulation of Steroid Hormone Receptor Function By the 52-kDa FK506-Binding Protein (FKBP52). Current Opinion in Pharmacology, 11, 314-319.
https://doi.org/10.1016/j.coph.2011.03.010

[106]   Wang, L. (2011) FKBP51 Regulation of AKT/Protein Kinase B Phosphorylation. Current Opinion in Pharmacology, 11, 360-364.
https://doi.org/10.1016/j.coph.2011.03.008

[107]   Li, L., Lou, Z. and Wang, L. (2011) The Role of FKBP5 in Cancer Aetiology and Chemoresistance. British Journal of Cancer, 104, 19-23.
https://doi.org/10.1038/sj.bjc.6606014

[108]   Jirawatnotai, S., Sharma, S., Michowski, W., et al. (2014) The Cyclin D1-CDK4 Oncogenic Interactome Enables Identification of Potential Novel Oncogenes and Clinical Prognosis. Cell Cycle, 13, 2889-2900.
https://doi.org/10.4161/15384101.2014.946850

[109]   Bhushan, L. and Kandpal, R.P. (2011) EphB6 Receptor Modulates Micro RNA Profile of Breast Carcinoma Cells. PLoS ONE, 6, e22484.
https://doi.org/10.1371/journal.pone.0022484

[110]   Yang, W.S., Moon, H.G., Kim, H.S., et al. (2012) Proteomic Approach Reveals FKBP4 and S100A9 as Potential Prediction Markers of Therapeutic Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer. Journal of Proteome Research, 11, 1078-1088.
https://doi.org/10.1021/pr2008187

[111]   Vahora, H., Khan, M.A., Alalami, U. and Hussain, A. (2016) The Potential Role of Nitric Oxide in Halting Cancer Progression through Chemoprevention. Journal of Cancer Prevention, 21, 1-12.
https://doi.org/10.15430/JCP.2016.21.1.1

[112]   Choudhari, S.K., Chaudhary, M., Bagde, S., Gadbail, A.R. and Joshi, V. (2013) Nitric Oxide and Cancer: A Review. World Journal of Surgical Oncology, 11, 118.
https://doi.org/10.1186/1477-7819-11-118

[113]   MacLauchlan, S., Yu, J., Parrish, M., Asoulin, T.A., Schleicher, M. and Krady, M.M. (2011) Endothelial Nitric Oxide Synthase Controls the Expression of the Angiogenesis Inhibitor Thrombospondin 2. Proceedings of the National Academy of Sciences of the United States of America, 108, E1137-E1145.
https://doi.org/10.1073/pnas.1104357108

[114]   Chang, C.F., Diers, A.R. and Hogg, N. (2015) Cancer Cell Metabolism and the Modulating Effects of Nitric Oxide. Free Radical Biology & Medicine, 79, 324-336.
https://doi.org/10.1016/j.freeradbiomed.2014.11.012

[115]   Rashad, Y.A., Elkhodary, T.R., El-Gayar, A.M. and Eissa, L.A. (2013) Evaluation of Serum Levels of HER2, MMP-9, Nitric Oxide, and Total Antioxidant Capacity in Egyptian Breast Cancer Patients: Correlation with Clinico-Pathological Parameters. Scientia Pharmaceutica, 82, 129-145.
https://doi.org/10.3797/scipharm.1306-18

[116]   Xiao, X., Li, B.X., Mitton, B., Ikeda, A. and Sakamoto, K.M. (2010) Targeting CREB for Cancer Therapy: Friend or Foe. Current Cancer Drug Targets, 10, 384-391.
https://doi.org/10.2174/156800910791208535

[117]   Alda, M., Shao, L., Wang, J.F., et al. (2013) Alterations in Phosphorylated cAMP Response Element-Binding Protein (pCREB) Signaling: An Endopheno-Type of Lithium-Responsive Bipolar Disorder? Bipolar Disorders, 15, 824-831.
https://doi.org/10.1111/bdi.12131

[118]   Molnar, P., Perraulft, R., Louis, S. and Zahradka, P. (2014) The Cyclic AMP Response Element-Binding Protein (CREB) Mediates Smooth Muscle Cell Proliferation in Response to Angiotensin II. Journal of Cell Communication and Signaling, 8, 29-37.
https://doi.org/10.1007/s12079-013-0215-5

[119]   Huang, S., Ren, Y., Wang, P., et al. (2015) Transcription Factor CRED in Involved in CaSR-Mediated Cytoskeleton Gene Expression. The Anatomical Record, 298, 501-512.
https://doi.org/10.1002/ar.23089

[120]   Li, X., Han, X., Llano, J., et al. (2011) Mammalian Target of Rapamycin Inhibition in Macrophages of Asymptomatic HIV+ Persons Reverses the Decrease in TLR-4-Mediated TNF-α Release through Prolongation of MAPK Pathway Activation. The Journal of Immunology, 187, 6052-6058.
https://doi.org/10.4049/jimmunol.1101532

[121]   Afonyushkin, T., Oskolkova, O.V., Philippova, M., et al. (2010) Oxidized Phospholipids Regulate Expression of ATF4 and VEGF in Endothelial Cells via NRF2-Dependent Mechanism: Novel Point of Convergence between Electrophilic and Unfolded Protein Stress Pathways. Arteriosclerosis, Thrombosis, and Vascular Biology, 30, 1007-1013.
https://doi.org/10.1161/ATVBAHA.110.204354

[122]   Son, J., Lee. J.H., Kim, H.N., Ha, H. and Lee, Z.H. (2010) cAMP-Response Element-Binding Protein Positively Regulates Breast Cancer Metastasis and Subsequent Bone Destruction. Biochemical and Biophysical Research Communications, 398, 309-314.
https://doi.org/10.1016/j.bbrc.2010.06.087

[123]   Fan, C.F., Mao, X.Y. and Wang, E.H. (2012) Elevated p-CREB-2 (ser 245) Expression Is Potentially Associated with Carcinogenesis and Development of Breast Carcinoma. Molecular Medicine Reports, 5, 357-362.

[124]   Singh, R., Shankar, B.S. and Sainis, K.B. (2014) TGF-β1-ROS-ATM-CREB Signaling Axis in Macrophage Mediated Migration of Human Breast Cancer MCF7 Cells. Cell Signal, 26, 1604-1615.
https://doi.org/10.1016/j.cellsig.2014.03.028

[125]   Steven, A., Leisz, S., Massa, C., et al. (2013) HER-2/Neu Mediates Oncogenic Transformation via Altered CREB Expression and Function. Molecular Cancer Research, 11, 1462-1477.
https://doi.org/10.1158/1541-7786.MCR-13-0125

[126]   Saldanha, C.J., Remage-Healey, L. and Schlinger, B.A. (2011) Synaptocrine Signaling: Steroid Synthesis and Action at the Synapse. Endocrine Reviews, 32, 532-549.
https://doi.org/10.1210/er.2011-0004

[127]   Aka, J.A., Zerradi, M., Houle, F., Huot, J. and Lin, S.X. (2012) 17β-Hydroxysteroid Dehydrogenase Type 1 Modulates Breast Cancer Protein Profile and Impacts Cell Migration. Breast Cancer Research, 13, R92.
https://doi.org/10.1186/bcr3207

[128]   Russo, J., Fernandez, S.V., Russo, P.A., Fernbaugh, R., Sheriff, F.S., Lareef, H.M., Garber, J. and Russo, I.H. (2006) 7-Beta-Estradiol Induces Transformation and Tumorigenesis in Human Breast Epithelial Cells. The FASEB Journal, 20, 1622-1634.
https://doi.org/10.1096/fj.05-5399com

[129]   Jordan, V.C. and Ford, L.G. (2011) Paradoxical Clinical Effect of Estrogen on Breast Cancer Risk: A “New” Biology of Estrogen-Induced Apoptosis. Cancer Prevention Research, 4, 633-637.
https://doi.org/10.1158/1940-6207.CAPR-11-0185

[130]   Zheng, S., Huang, J., Zhou, K., Zhang, C., Xiang, Q., Tan, Z., Wang, T. and Fu, X. (2011) 17β-Estradiol Enhances Breast Cancer Cell Motility and Invasion via Extranuclear Activation of Actin-Binding Protein Ezrin. PLoS ONE, 6, e22439.
https://doi.org/10.1371/journal.pone.0022439

[131]   Pattarozzi, A., Gatti, M., Barbieri, F., Wurth, R., Porcile, C., Lunardi, G., Ratto, A., Favoni, R., Bajetto, A., Ferrari, A., et al. (2008) 17beta-Estradiol Promotes Breast Cancer Cell Proliferation-Inducing Stromal Cell-Derived Factor-1-Mediated Epidermal Growth Factor Receptor Transactivation: Reversal by Gefitinib Pretreatment. Molecular Pharmacology, 73, 191-202.
https://doi.org/10.1124/mol.107.039974

[132]   Loffek, S., Schilling, O. and Franzke, C.W. (2011) Biological Role of Matrix Metalloproteinases: A Critical Balance. The European Respiratory Journal, 38, 191-208.
https://doi.org/10.1183/09031936.00146510

[133]   Nagase, H., Visse, R. and Murphy, G. (2006) Structure and Function of Matrix Metalloproteinases and TIMPs. Cardiovascular Research, 69, 562-573.
https://doi.org/10.1016/j.cardiores.2005.12.002

[134]   Lu, P., Takai, K., Weaver, V.M. and Werb, Z. (2011) Extracellular Matrix Degradation and Remodeling in Development and Disease. Cold Spring Harbor Perspectives in Biology, 3, a005058.
https://doi.org/10.1101/cshperspect.a005058

[135]   Tallant, C., Marrero, A. and Gomis-Ruth, F.X. (2010) Matrix Metalloproteinases: Fold and Function of Their Catalytic Domains. BBA Molecular Cell Research, 1803, 20-28.
https://doi.org/10.1016/j.bbamcr.2009.04.003

[136]   Benson, C.S., Babu, S.D., Radhakrishna, S., Selvamurugan, N. and Sankar, B.R. (2013) Expression of Matrix Metalloproteinases in Human Breast Cancer Tissues. Disease Markers, 34, 395-405.
https://doi.org/10.1155/2013/420914

[137]   Rizwan, A., Cheng, M., Bhujwalla, Z.M., Jiang, L. and Glunde, K. (2015) Breast Cancer Cell Adhesome and Degradome Interact to Drive Metastasis. NPJ Breast Cancer, 1, Article No. 15017.
https://doi.org/10.1038/npjbcancer.2015.17

[138]   Gialeli, C., Theocharis, A.D. and Karamanos, N.K. (2011) Roles of Matrix Metallo-Proteinases in Cancer Progression and Their Pharmacological Targeting. The FEBS Journal, 278, 16-27.
https://doi.org/10.1111/j.1742-4658.2010.07919.x

[139]   Koujan, S.E., Gargarib, B.P., Pirouzpanah, S. and Khalili, M. (2015) Matrix Metalloproteinases and Breast Cancer. Thrita, 4, e21959.

[140]   Liu, H., Kato, Y., Erzinger, S.A., et al. (2012) The Role of MMP-1 in Breast Cancer Growth and Metastasis to the Brain in a Xenograft Model. BMC Cancer, 12, 583.
https://doi.org/10.1186/1471-2407-12-583

[141]   Zhang, L., Sullivan, P., Suyama, J. and Marchetti, D. (2010) Epidermal Growth Factor-Induced Heparanase Nucleolar Localization Augments DNA Topoisomerase I Activity in Brain Metastatic Breast Cancer. Molecular Cancer Research, 8, 278-290.
https://doi.org/10.1158/1541-7786.MCR-09-0375

[142]   Ring, H., Mendu, S.K., Shirazi-Fard, S., Birnir, B. and Hallbook, F. (2012) GABA Maintains the Proliferation of Progenitors in the Developing Chick Ciliary Marginal Zone and Non-Pigmented Ciliary Epithelium. PLoS ONE, 7, e36874.
https://doi.org/10.1371/journal.pone.0036874

[143]   Soltani, N., Qiu, H., Aleksic, M., Glinka, Y., Zhao, F., Liu, R., Li, Y., Zhang, N., Chakrabarti, R. and Ng, T. (2011) GABA Exerts Protective and Regenerative Effects on Islet Beta Cells and Reverses Diabetes. Proceedings of the National Academy of Sciences of the United States of America, 108, 11692-11697.
https://doi.org/10.1073/pnas.1102715108

[144]   Li, Y.H., Liu, Y., Li, Y.D., Liu, Y.H., Li, F., Ju, Q., Xie, P.L. and Li, G.C. (2012) GABA Stimulates Human Hepatocellular Carcinoma Growth through Overexpressed GABAA Receptor Theta Subunit. World Journal of Gastroenterology, 18, 2704-2711.
https://doi.org/10.3748/wjg.v18.i21.2704

[145]   Andang, M., Hjerling-Leffler, J., Moliner, A., Lundgren, T.K., Castelo-Branco, G., Nanou, E., Pozas, E., Bryja, V., Halliez, S. and Nishimaru, H. (2008) Histone H2AX-Dependent GABA(A) Receptor Regulation of Stem Cell Proliferation. Nature, 451, 460-464.
https://doi.org/10.1038/nature06488

[146]   Chen, Z.A., Bao, M.Y., Xu, Y.F., Zha, R.P., Shi, H.B., Chen, T.Y. and He, X.H. (2012) Suppression of Human Liver Cancer Cell Migration and Invasion via the GABAA Receptor. Cancer Biology & Medicine, 9, 90-98.

[147]   Wu, W. (2014) Abstract 3309: Castration-Resistant Prostate Cancer (CRPC) Growth Is Mediated through Gama-Aminobutyric Acid a Receptor (GABAAR). Cancer Research, 74, 3309.
https://doi.org/10.1158/1538-7445.AM2014-3309

[148]   Zhang, D., Li, X., Yao, Z., Wei, C., Ning, N. and Li, J. (2014) GABAergic Signaling Facilitates Breast Cancer Metastasis by Promoting ERK1/2-Dependent Phosphorylation. Cancer Letters, 348, 100-108.
https://doi.org/10.1016/j.canlet.2014.03.006

[149]   Bortsov, A.V., Millikan, R.C., Belfer, I., Boortz-Marx, R.L., Arora, H. and McLean, S.A. (2012) μ-Opioid Receptor Gene A118G Polymorphism Predicts Survival in Patients with Breast Cancer. Anesthesiology, 116, 896-902.
https://doi.org/10.1097/ALN.0b013e31824b96a1

[150]   Cieslinska, A., Sienkiewicz-Szlapka, E., Kostyra, E., et al. (2015) μ-Opioid Receptor Gene (OPRM1) Polymorphism in Patients with Breast Cancer. Tumour Biology, 36, 4655-4660.
https://doi.org/10.1007/s13277-015-3113-z

[151]   Singleton, P.A., Mirzapoiazova, T., Hasina, R., Salgia, R. and Moss, J. (2014) Increased μ-Opioid Receptor Expression in Metastatic Lung Cancer. British Journal of Anaesthesia, 113, i103-i108.
https://doi.org/10.1093/bja/aeu165

[152]   Roy, S., Ninkovic, J., Banerjee, S., Charboneau, R.G., Das, S., Dutta, R., Kirchner, V.A., Koodie, L., Ma, J., Meng, J. and Barke, R.A. (2011) Opioid Drug Abuse and Modulation of Immune Function: Consequences in the Susceptibility to Opportunistic Infections. Journal of NeuroImmune Pharmacology, 6, 442-465.
https://doi.org/10.1007/s11481-011-9292-5

[153]   Cata, J.P., Bugada, D., Marchesini, M., Gregori, M.D. and Allegri, M. (2016) Opioids and Cancer Recurrence: A Brief Review of the Literature. Cancer Cell & Microenvironment, 3, e1159.

[154]   Merkle, D. and Hoffmann, R. (2011) Roles of cAMP and cAMP-Dependent Protein Kinase in the Progression of Prostate Cancer: Cross-Talk with the Androgen Receptor. Cell Signal, 23, 507-515.
https://doi.org/10.1016/j.cellsig.2010.08.017

[155]   El-Mowafy, A.M. and Alkhalaf, M. (2003) Resveratrol Activates Adenylyl-Cyclase in Human Breast Cancer Cells: A Novel, Estrogen Receptor-Independent Cytostatic Mechanism. Carcinogenesis, 24, 869-873.
https://doi.org/10.1093/carcin/bgg015

[156]   Pisanti, S., Malfitano, A.M., Grimaldi, C., Santoro, A., Gazzerro, P., Laezza, C., et al. (2009) Use of Cannabinoid Receptor Agonists in Cancer Therapy as Palliative and Curative Agents. Best Practice & Research: Clinical Endocrinology & Metabolism, 23, 117-131.
https://doi.org/10.1016/j.beem.2009.02.001

[157]   Gu, Y., Chen, T., Lopez, E., Wu, W., Wang, X., Cao, J. and Teng, L. (2014) The Therapeutic Target of Estrogen Receptor-alpha36 in Estrogen-Dependent Tumors. Journal of Translational Medicine, 12, 16.
https://doi.org/10.1186/1479-5876-12-16

[158]   Levin, E.R. (2012) Elusive Extranuclear Estrogen Receptors in Breast Cancer. Clinical Cancer Research, 18, 6-8.
https://doi.org/10.1158/1078-0432.CCR-11-2547

[159]   Maggiolini, M. and Picard, D. (2010) The Unfolding Stories of GPR30, a New Membrane-Bound Estrogen Receptor. Journal of Endocrinology, 204, 105-114.
https://doi.org/10.1677/JOE-09-0242

[160]   Chambliss, K.L., Wu, Q., Oltmann, S., et al. (2010) Non-Nuclear Estrogen Receptor Alpha Signaling Promotes Cardiovascular Protection But Not Uterine or Breast Cancer Growth in Mice. Journal of Clinical Investigation, 120, 2319-2330.
https://doi.org/10.1172/JCI38291

[161]   Pelekanou, V., Notas, G., Kampa, M., Tsentelierou, E., Radojicic, J., Leclercq, G., Castanas, E. and Stathopoulos, E.N. (2012) ERα36, a New Variant of the ERα Is Expressed in Triple Negative Breast Carcinomas and Has a Specific Transcriptomic Signature in Breast Cancer Cell Lines. Steroids, 77, 928-934.
https://doi.org/10.1016/j.steroids.2011.12.016

[162]   Ariazi, E.A., Brailoiu, E., Yerrum, S., et al. (2010) The G Protein-Coupled Receptor GPR30 Inhibits Proliferation of Estrogen Receptor-Positive Breast Cancer Cells. Cancer Research, 70, 1184-1194.
https://doi.org/10.1158/0008-5472.CAN-09-3068

[163]   Zhang, X., Kang, L., Ding, L., Vranic, S., Gatalica, Z. and Wang, Z.-Y. (2011) A Positive Feedback Loop of ER-α36/EGFR Promotes Malignant Growth of ER-Negative Breast Cancer Cells. Oncogene, 30, 770-780.
https://doi.org/10.1038/onc.2010.458

[164]   Wei, W., Chen, Z.-J., Zhang, K.-S., et al. (2014) The Activation of G Protein-Coupled Receptor 30 (GPR30) Inhibits Proliferation of Estrogen Receptor-Negative Breast Cancer Cells in Vitro and in Vivo. Cell Death & Disease, 5, e1428.
https://doi.org/10.1038/cddis.2014.398

[165]   Weiβenborn, C., Ignatov, T., Ochel, H.J., et al. (2014) GPER Functions as a Tumor Suppressor in Triple-Negative Breast Cancer Cells. Journal of Cancer Research and Clinical Oncology, 140, 713-723.
https://doi.org/10.1007/s00432-014-1620-8

[166]   Wang, D., Hu, L., Zhang, G., Zhang, L. and Chen, C. (2010) G Protein-Couples Receptor 30 in Tumor Development. Endocrine, 38, 29-37.
https://doi.org/10.1007/s12020-010-9363-z

[167]   Lappano, R., Santolla, M.F., Pupo, M., et al. (2012) MIBE Acts as Antagonist Ligand of Both Estrogen Receptor α and GPER in Breast Cancer Cells. Breast Cancer Research, 14, R12.
https://doi.org/10.1186/bcr3096

[168]   Ignatov, A., Ignatov, T., Roessner, A., Costa, S.D. and Kalinski, T. (2010) Role of GPR30 in the Mechanisms of Tamoxifen Resistance in Breast Cancer MCF-7 Cells. Breast Cancer Research and Treatment, 123, 87-96.
https://doi.org/10.1007/s10549-009-0624-6

[169]   Lemmon, M.A. and Schlessinger, J. (2010) Cell Signaling by Receptor Tyrosine Kinases. Cell, 141, 1117-1134.
https://doi.org/10.1016/j.cell.2010.06.011

[170]   Oku, S., van der Meulen, T., Copp, J., Glenn, G. and van der Geer, P. (2012) Engineering NGF Receptors to Bind Grb2 Directly Uncovers Differences in Signaling Ability between Grb2- and ShcA-Binding Sites. FEBS Letters, 586, 3658-3664.
https://doi.org/10.1016/j.febslet.2012.08.021

[171]   Lucs, A.V., Muller, W.J. and Muthuswamy, S.K. (2010) Shc Is Required for ErbB2-Induced Inhibition of Apoptosis But Is Dispensable for Cell Proliferation and Disruption of Cell Polarity. Oncogene, 29, 174-187.
https://doi.org/10.1038/onc.2009.312

[172]   Wills, M.K. and Jones, N. (2012) Teaching an Old Dogma New Tricks: Twenty Years of Shc Adaptor Signalling. Biochemical Journal, 447, 1-16.
https://doi.org/10.1042/BJ20120769

[173]   Zheng, Y., Zhang, C., Croucher, D.R., Soliman, M.A., St-Denis, N., Pasculescu, A., Taylor, L., Tate, S.A., Hardy, W.R., Colwill, K., Dai, A.Y., Bagshaw, R., Dennis, J.W., Gingras, A.C., Daly, R.J. and Pawson, T. (2013) Temporal Regulation of EGF Signalling Networks by the Scaffold Protein Shc1. Nature, 499, 166-171.
https://doi.org/10.1038/nature12308

[174]   Northey, J.J., Dong, Z., Ngan, E., Kaplan, A., Hardy, W.R., Pawson, T. and Siegel, P.M. (2013) Distinct Phosphotyrosine-Dependent Functions of the ShcA Adaptor Protein Are Required for Transforming Growth Factor Beta (TGFbeta)-Induced Breast Cancer Cell Migration, Invasion, and Metastasis. The Journal of Biological Chemistry, 288, 5210-5222.
https://doi.org/10.1074/jbc.M112.424804

[175]   Rajendran, M., Thomes, P., Zhang, L., Veeramani, S. and Lin, M.-F. (2010) p66Shc—A Longevity Redox Protein in Human Prostate Cancer Progression and Metastasis: p66Shc in Cancer Progression and Metastasis. Cancer and Metastasis Reviews, 29, 207-222.
https://doi.org/10.1007/s10555-010-9213-8

[176]   Ma, Z., Liu, Z., Wu, R.-F. and Terada, L. (2010) p66Shc Restrains Ras Hyperactivation and Suppresses Metastatic Behavior. Oncogene, 29, 5559-5567.
https://doi.org/10.1038/onc.2010.326

[177]   Hudson, J., Ha, J.R., Sabourin, V., et al. (2014) p66ShcA Promotes Breast Cancer Plasticity by Inducing an Epithelial-to-Mesenchymal Transition. Molecular and Cellular Biology, 34, 3689-3701.
https://doi.org/10.1128/MCB.00341-14

[178]   Haines, E., Saucier, C. and Claing, A. (2014) The Adaptor Proteins p66Shc and Grb2 Regulate the Activation of the GTPases ARF1 and ARF6 in Invasive Breast Cancer Cells. The Journal of Biological Chemistry, 289, 5687-5703.
https://doi.org/10.1074/jbc.M113.516047

[179]   Sassone-Corsi, P. (2012) The Cyclic AMP Pathway. Cold Spring Harbor Perspectives in Biology, 4, a011148.
https://doi.org/10.1101/cshperspect.a011148

[180]   Lee, L.C., Maurice, D.H. and Baillie, G.S. (2013) Targeting Protein-Protein Interactions within the Cyclic AMP Signaling System as a Therapeutic Strategy for Cardiovascular Disease. Future Medicinal Chemistry, 5, 451-464.
https://doi.org/10.4155/fmc.12.216

[181]   Fajardo, A.M., Piazza, G.A. and Tinsley, H.N. (2014) The Role of Cyclic Nucleotide Signaling Pathways in Cancer: Targets for Prevention and Treatment. Cancers, 6, 436-458.
https://doi.org/10.3390/cancers6010436

[182]   Follin-Arbelet, V., Hofgaard, P.O., Hauglin, H., et al. (2011) Cyclic AMP Induces Apoptosis in Multiple Myeloma Cells and Inhibits Tumor Development in a Mouse Myeloma Model. BMC Cancer, 11, 301.
https://doi.org/10.1186/1471-2407-11-301

[183]   Dong, H., Claffey, K.P., Brocke, S. and Epstein, P.M. (2015) Inhibition of Breast Cancer Cell Migration by Activation of cAMP Signaling. Breast Cancer Research and Treatment, 152, 17-28.
https://doi.org/10.1007/s10549-015-3445-9

[184]   Pon, C.K., Lane, J.R., Sloan, E.K. and Halls, M.L. (2016) The β2-Adrenoceptor Activates a Positive cAMP-Calcium Feedforward Loop to Drive Breast Cancer Cell Invasion. The FASEB Journal, 30, 1144-1154.
https://doi.org/10.1096/fj.15-277798

[185]   Vanhaesebroeck, B., Vogt, P.K. and Rommel, C. (2011) PI3K-From the Bench to the Clinic and Back. Current Topics in Microbiology and Immunology, 347, 1-19.

[186]   Baselga, J. (2011) Targeting the Phosphoinositide-3 (PI3) Kinase Pathway in Breast Cancer. The Oncologist, 16, 12-19.
https://doi.org/10.1634/theoncologist.2011-S1-12

[187]   Loi, S., Haibe-Kains, B., Majjaj, S., et al. (2010) PIK3CA Mutations Associated with Gene Signature of Low mTORC1 Signaling and Better Outcomes in Estrogen Receptor-Positive Breast Cancer. Proceedings of the National Academy of Sciences of the United States of America, 107, 10208-10213.
https://doi.org/10.1073/pnas.0907011107

[188]   Baselga, J., Semiglazov, V., van Dam, P., et al. (2009) Phase II Randomized Study of Neoadjuvant Everolimus plus Letrozole Compared with Placebo plus Letrozole in Patients with Estrogen Receptor-Positive Breast Cancer. Journal of Clinical Oncology, 27, 2630-2637.
https://doi.org/10.1200/JCO.2008.18.8391

[189]   Ellis, M.J., Lin, L., Crowder, R., Tao, Y., et al. (2010) Phosphatidyl-Inositol-3-Kinase Alpha Catalytic Subunit Mutation and Response to Neoadjuvant Endocrine Therapy for Estrogen Receptor Positive Breast Cancer. Breast Cancer Research and Treatment, 119, 379-390.
https://doi.org/10.1007/s10549-009-0575-y

[190]   Perez-Tenorio, G., Alkhori, L., Olsson, B., et al. (2007) PIK3CA Mutations and PTEN Loss Correlate with Similar Prognostic Factors and Are Not Mutually Exclusive in Breast Cancer. Clinical Cancer Research, 13, 3577-3584.
https://doi.org/10.1158/1078-0432.CCR-06-1609

[191]   Miller, T.W., Rexer, B.N., Garrett, J.T. and Arteaga, C.L. (2011) Mutations in the Phosphatidylinositol 3-Kinase Pathway: Role in Tumor Progression and Therapeutic Implications in Breast Cancer. Breast Cancer Research, 13, 224.
https://doi.org/10.1186/bcr3039

[192]   Castaneda, C.A., Lopez-Ilasaca, M., Pinto, J.A., et al. (2014) PIK3CA Mutations in Peruvian Patients with HER2-Amplified and Triple Negative Non-Metastatic Breast Cancers. Hematology/Oncology and Stem Cell Therapy, 7, 142-148.
https://doi.org/10.1016/j.hemonc.2014.09.007

[193]   Juric, D. and Baselga, J. (2012) Tumor Genetic Testing for Patient Selection in Phase I Clinical Trials: The Case of PI3K Inhibitors. Journal of Clinical Oncology, 30, 765-766.
https://doi.org/10.1200/JCO.2011.39.6390

[194]   Urtreger, A.J., Kazanietz, M.G. and Bal de Kier Joffe, E.D. (2012) Contribution of Individual PKC Isoforms to Breast Cancer Progression. IUBMB Life, 64, 18-26.
https://doi.org/10.1002/iub.574

[195]   Basu, A. and Pal, D. (2010) Two Faces of Protein Kinase Cdelta: The Contrasting Roles of PKCdelta in Cell Survival and Cell Death. The Scientific World Journal, 10, 2272-2284.
https://doi.org/10.1100/tsw.2010.214

[196]   Luna-Ulloa, L.B., Hernandez-Maqueda, J.G., Castaneda-Patlan, M.C. and Robles-Flores, M. (2011) Protein Kinase C in Wnt Signaling: Implications in Cancer Initiation and Progression. IUBMB Life, 63, 915-921.
https://doi.org/10.1002/iub.559

[197]   Chen, Z., Forman, L.W., Williams, R.M. and Faller, D.V. (2014) Protein Kinase C-δ Inactivation Inhibits the Proliferation and Survival of Cancer Stem Cells in Culture and in Vivo. BMC Cancer, 14, 90.
https://doi.org/10.1186/1471-2407-14-90

[198]   Belle, L., Ali, N., Lonic, A., et al. (2015) The Tyrosine Phosphatase PTPN14 (Pez) Inhibits Metastasis by Altering Pteoin Trafficking. Science Signaling, 8, RA18.
https://doi.org/10.1126/scisignal.2005547

[199]   Lonne, G.K., Cornmark, L., Zahirovic, I.O., Landberg, G., Jirstrom, K. and Larsson, C. (2010) PKCα Expression Is a Marker for Breast Cancer Aggressiveness. Molecular Cancer, 9, 76.
https://doi.org/10.1126/scisignal.2005547

[200]   Diaz Bessone, M.I., Berardi, D.E., Campodonico, P.B., et al. (2011) Involvement of PKC delta (PKCdelta) in the Resistance against Different Doxorubicin Analogs. Breast Cancer Research Treat, 126, 577-587.
https://doi.org/10.1007/s10549-010-0956-2

[201]   Allen-Petersen, B.L., Carter, C.J., Ohm, A.M. and Reyland, M.E. (2014) Protein Kinase Cδ Is Required for ErbB2-Driven Mammary Gland Tumorigenesis and Negatively Correlates with Prognosis in Human Breast Cancer. Oncogene, 33, 1306-1315.
https://doi.org/10.1038/onc.2013.59

[202]   Zuo, Y., Wu, Y. and Chakraborty, C. (2012) Cdc42 Negatively Regulates Intrinsic Migration of Highly Aggressive Breast Cancer Cells. Journal of Cellular Physiology, 227, 1399-1407.
https://doi.org/10.1002/jcp.22853

[203]   McKenzie, A.J., Campbell, S.L. and Howe, A.K. (2011) Protein Kinase A Activity and Anchoring Are Required for Ovarian Cancer Cell Migration and Invasion. PLoS ONE, 6, e26552.
https://doi.org/10.1371/journal.pone.0026552

[204]   Bentin Toaldo, C., Alexi, X., Beelen, K., et al. (2015) Protein Kinase A—Induced Tamoxifen Resistance Is Mediated by Anchoring Protein AKAP13. BMC Cancer, 15, 588.
https://doi.org/10.1186/s12885-015-1591-4

[205]   Sarwar, M. and Persson, J.L. (2012) The Protein Kinase A (PKA) Intracellular Pathway and Androgen Receptor: A Novel Mechanism Underlying the Castration-Resistant and Metastatic Prostate Cancer. Journal of Cancer Science and Therapy, 4, 1.
https://doi.org/10.4172/1948-5956.S5-003

[206]   Donini, C.F., Di Zazzo, E., Zuchegna, C., et al. (2012) The p85α Regulatory Subunit of PI3K Mediates cAMP-PKA and Retinoic Acid Biological Effects on MCF-7 Cell Growth and Migration. International Journal of Oncology, 40, 1627-1635.

[207]   Mao, L., Yuan, L., Slakey, L.M., Jones, F.E., Burow, M.E. and Hill, S.M. (2010) Inhibition of Breast Cancer Cell Invasion by Melatonin Is Mediated through Regulation of the p38 Mitogen-Activated Protein Kinase Signaling Pathway. Breast Cancer: BCR, 12, R107.
https://doi.org/10.1186/bcr2794

[208]   Beristain, A.G., Molyneux, S.D., Joshi, P.A., Pomroy, N.C., Di Grappa, M.A., et al. (2015) PKA Signaling Drives Mammary Tumorigenesis through Src. Oncogene, 34, 1160-1173.
https://doi.org/10.1038/onc.2014.41

[209]   Liao, X.H., Wang, Y., Wang, N., et al. (2014) Human Chorionic Gonadotropin Decreases Human Breast Cancer Cell Proliferation and Promotes Differentiation. IUBMB Life, 66, 352-360.
https://doi.org/10.1002/iub.1269

[210]   Yang, Y.R., Choi, J.H., Chang, J.S., et al. (2012) Diverse Cellular and Physiological Roles of Phospholipase C-γ1. Advances in Biological Regulation, 52, 138-151.
https://doi.org/10.1016/j.advenzreg.2011.09.017

[211]   Raimondi, C. and Falasca, M. (2012) Phosphoinositides Signalling in Cancer: Focus on PI3K and PLC. Advances in Biological Regulation, 52, 166-182.
https://doi.org/10.1016/j.advenzreg.2011.09.016

[212]   Kadamur, G. and Ross, E.M. (2013) Mammalian Phospholipase C. Annual Review of Physiology, 75, 127-154.
https://doi.org/10.1146/annurev-physiol-030212-183750

[213]   Lattanzio, R., Marchisio, M., La Sorda, R., et al. (2013) Overexpression of Activated Phospholipase Cγ1 Is a Risk Factor for Distant Metastases in T1-T2, N0 Breast Cancer Patients Undergoing Adjuvant Chemotherapy. International Journal of Cancer, 132, 1022-1031.
https://doi.org/10.1002/ijc.27751

[214]   Bunney, T.D. and Katan, M. (2011) PLC Regulation: Emerging Pictures for Molecular Mechanisms. Trends in Biochemical Sciences, 36, 88-96.
https://doi.org/10.1016/j.tibs.2010.08.003

[215]   Balz, L.M., Bartkowiak, K., Andreas, A., et al. (2012) The Interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 Signaling in Breast Cancer Cell Migration and Dissemination. The Journal of Pathology, 227, 234-244.
https://doi.org/10.1002/path.3991

[216]   Brugnoli, F., Grassilli, S., Piazzi, M., et al. (2013) In Triple Negative Breast Tumor Cells, PLC-β2 Promotes the Conversion of CD133 High to CD133 Low Phenotype and Reduces the CD133-Related Invasiveness. Molecular Cancer, 12, 165.
https://doi.org/10.1186/1476-4598-12-165

[217]   Marchi, S., Marinello, M., Bononi, A., et al. (2012) Selective Modulation of Subtype III IP3R by Akt Regulates ER Ca2+ Release and Apoptosis. Cell Death & Disease, 3, e304.
https://doi.org/10.1038/cddis.2012.45

[218]   Akimzhanov, A.M. and Boehning, D. (2012) IP3R Function in Cells of the Immune System. Wiley Interdisciplinary Reviews: Membrane Transport and Signaling, 1, 329-339.
https://doi.org/10.1002/wmts.27

[219]   Rudiger, S., Jung, P. and Shuai, J.-W. (2012) Termination of Ca2+ Release for Clustered IP3R Channels. PLoS Computational Biology, 8, e1002485.
https://doi.org/10.1371/journal.pcbi.1002485

[220]   Serysheva, I.I. (2014) Toward a High-Resolution Structure of IP3R Channel. Cell Calcium, 56, 125-132.
https://doi.org/10.1016/j.ceca.2014.08.002

[221]   Szatkowski, C., Parys, J.B., Ouadid-Ahidouch, H. and Matifat, F. (2010) Inositol 1,4,5-Trisphosphate-Induced Ca2+ Signalling Is Involved in Estradiol-Induced Breast Cancer Epithelial Cell Growth. Molecular Cancer, 9, 156.
https://doi.org/10.1186/1476-4598-9-156

[222]   Andruska, N., Zheng, X., Yang, X., Helferich, W.G. and Shapiro, D.J. (2015) Anticipatory Estrogen Activation of the Unfolded Protein Response Is Linked to Cell Proliferation and Poor Survival in Estrogen Receptor α Positive Breast Cancer. Oncogene, 34, 3760-3769.

[223]   Hedgepeth, S.C., Garcia, M.I., Wagner, L.E., et al. (2015) The BRCA1 Tumor Suppressor Binds to Inositol 1,4,5-Trisphosphate Receptors to Stimulate Apoptotic Calcium Release. The Journal of Biological Chemistry, 290, 7304-7313.
https://doi.org/10.1074/jbc.M114.611186

[224]   Akl, H. and Bultynck, G. (2013) Altered Ca2+ Signaling in Cancer Cells: Proto-Oncogenes and Tumor Suppressors Targeting IP3 Receptors. Biochimica et Biophysica Acta, 1835, 180-193.
https://doi.org/10.1016/j.bbcan.2012.12.001

[225]   Prabhu, V. and Guruyayoorappan, C. (2010) Nitric Oxide: Pros and Cons in Tumor Progression. Immunopharmacology and Immunotoxicology, 32, 387-392.
https://doi.org/10.3109/08923970903440192

[226]   Qian, J. and Fulton, D. (2013) Post-Translational Regulation of Endothelial Nitric Oxide Synthase in Vascular Endothelium. Frontiers in Physiology, 4, 347.
https://doi.org/10.3389/fphys.2013.00347

[227]   Green, D.J. (2009) Exercise Training as Vascular Medicine: Direct Impacts on the Vasculature in Humans. Exercise and Sport Sciences Reviews, 37, 196-202.

[228]   Gao, X., Wang, J., Wang, W., Wang, M. and Zhang, J. (2015) eNOS Genetic Polymorphisms and Cancer Risk: A Meta-Analysis and a Case-Control Study of Breast Cancer. Medicine, 94, e972.
https://doi.org/10.1097/MD.0000000000000972

[229]   Zhang, L., Chen, L.M., Wang, M.N., et al. (2014) The G894t, T-786c and 4b/a Polymorphisms in Enos Gene and Cancer Risk: A Meta-Analysis. Journal of Evidence-Based Medicine, 7, 263-269.
https://doi.org/10.1111/jebm.12126

[230]   Zintzaras, E., Grammatikou, M., Kitsios, G.D., et al. (2010) Polymorphisms of the Endothelial Nitric Oxide Synthase Gene in Breast Cancer: A Genetic Association Study and Meta-Analysis. Journal of Human Genetics, 55, 743-748.
https://doi.org/10.1038/jhg.2010.100

[231]   Haque, S., Mandal, R.K. and Akhter, N. (2015) G89RT and 4a/b Polymorphisms of NOS3 Gene Are Not Associated with Cancer Risk: A Meta-Analysis. Asian Pacific Journal of Cancer Prevention, 16, 2929-2937.
https://doi.org/10.7314/APJCP.2015.16.7.2929

[232]   Zhang, L., Zeng, M. and Fu, B.M. (2016) Inhibition of Endothelial Nitric Oxide Synthase Decreases Breast Cancer Cell MDA-MB-231 Adhesion to Intact Microvessels under Physiological Flows. American Journal of Physiology-Heart and Circulatory Physiology, 310, H1735-H1747.
https://doi.org/10.1152/ajpheart.00109.2016

[233]   Liu, B., Fu, L., Zhang, C., et al. (2015) Computational Design, Chemical Synthesis, and Biological Evaluation of a Novel ERK Inhibitor (BL-EI001) with Apoptosis-Inducing Mechanisms in Breast Cancer. Oncotarget, 6, 6762-6775.

[234]   Kim, E.K. and Choi, E.J. (2010) Pathological Roles of MAPK Signaling Pathways in Human Diseases. Biochimica et Biophysica Acta, 1802, 396-405.
https://doi.org/10.1016/j.bbadis.2009.12.009

[235]   Roskoski, R. (2012) ERK1/2 MAP Kinases: Structure, Function, and Regulation. Pharmacological Research, 66, 105-143.
https://doi.org/10.1016/j.phrs.2012.04.005

[236]   Hong, B., Li, H., Zhang, M., et al. (2015) p38 MAPK Inhibits Breast Cancer Metastasis through Regulation of Stromal Expansion. International Journal of Cancer, 136, 34-43.
https://doi.org/10.1002/ijc.28958

[237]   Ventura, C., Venturino, A., Miret, N., et al. (2015) Chlorpyrifos Inhibits Cell Proliferation through ERK1/2 Phosphorylation in Breast Cancer Cell Lines. Chemosphere, 120, 343-350.
https://doi.org/10.1016/j.chemosphere.2014.07.088

[238]   Laprevotte, E., Bastid, J., Cochaud, S., et al. (2015) Abstract 5027: Interleukin-17B Promotes Chemoresistance of Breast Tumor through ERK1/2 Anti-Apoptotic Pathway. Proceedings: AACR 106th Annual Meeting, 75, 18-22.
https://doi.org/10.1158/1538-7445.AM2015-5027

[239]   Boston, S.R., Deshmukh, R., Strome, S., Priyakumar, U.D., MacKerell, A.D. and Shapiro, P. (2011) Characterization of ERK Docking Domain Inhibitors That Induce Apoptosis by Targeting Rsk-1 and Caspase-9. BMC Cancer, 11, 7.
https://doi.org/10.1186/1471-2407-11-7

[240]   Kharman-Biz, A., Gao, H., Ghiasvand, R., Zhao, C., Zendehdel, K. and Dahlman-Wright, K. (2013) Expression of Activator Protein-1 (AP-1) Family Members in Breast Cancer. BMC Cancer, 13, 441.
https://doi.org/10.1186/1471-2407-13-441

[241]   Lopez-Bergami, P., Lau, E. and Ronai, Z. (2010) Emerging Roles of ATF2 and the Dynamic AP1 Network in Cancer. Nature Reviews Cancer, 10, 65-76.
https://doi.org/10.1038/nrc2681

[242]   Ueno, T., Utsumi, J., Toi, M. and Shimizu, K. (2015) Characteristic Gene Expression Profiles of Human Fibroblasts and Breast Cancer Cells in a Newly Developed Bilateral Coculture System. BioMed Research International, 2015, Article ID: 960840.
https://doi.org/10.1155/2015/960840

[243]   Dahlman-Wright, K., Qiao, Y., Jonsson, P., Gustafsson, J.A., Williams, C. and Zhao, C. (2012) Interplay between AP-1 and Estrogen Receptor α Regulating Gene Expression and Proliferation Networks in Breast Cancer Cells. Carcinogenesis, 33, 1684-1691.
https://doi.org/10.1093/carcin/bgs223

[244]   Belguise, K., Milord, S., Galtier, F., Moquet-Torcy, G., Piechaczyk, M. and Chalbos, D. (2012) The PKCθ Pathway Participates in the Aberrant Accumulation of Fra-1 Protein in Invasive ER-Negative Breast Cancer Cells. Oncogene, 31, 4889-4897.
https://doi.org/10.1038/onc.2011.659

[245]   Logullo, A.F., Stiepcich, M.M.A., de Toledo Osorio, C.A.B., et al. (2011) Role of Fos-Related Antigen 1 in the Progression and Prognosis of Ductal Breast Carcinoma. Histopathology, 58, 617-625.
https://doi.org/10.1111/j.1365-2559.2011.03785.x

[246]   Scroder, C., Schumacher, U., Muller, V., et al. (2010) The Transcription Factor Fra-2 Promotes Mammary Tumour Progression by Changing the Adhesive Properties of Breast Cancer Cells. European Journal of Cancer, 46, 1650-1660.
https://doi.org/10.1016/j.ejca.2010.02.008

[247]   Jiao, X., Katiyar, S., Willmarth, N.E., et al. (2010) c-Jun Induces Mammary Epithelial Cellular Invasion and Breast Cancer Stem Cell Expansion. The Journal of Biological Chemistry, 285, 8218-8226.
https://doi.org/10.1074/jbc.M110.100792

[248]   Gao, C., Weisman, D., Gou, N., Ilyin, V. and Gu, A.Z. (2012) Analyzing High Dimensional Toxicogenomic Data Using Consensus Clustering. Environmental Science & Technology, 46, 8413-8421.
https://doi.org/10.1021/es3000454

 
 
Top